Japan Study: Could a Natural Fatty Acid Help Control Blood Sugar After Meals?

A study from Japan has found that myristic acid — a naturally occurring saturated fatty acid found in coconut oil, palm kernel oil, and dairy products — may significantly reduce blood sugar spikes after meals in adults who are at risk for type 2 diabetes. Published in Clinical Nutrition ESPEN (2026), this is the first human clinical trial to demonstrate this effect, and the findings could have meaningful implications for the millions of Americans living with prediabetes.

What the Japanese Researchers Did

Scientists at J-OIL MILLS Research and Development Center in Yokohama recruited 100 healthy Japanese adults whose post-meal blood glucose peaked between 140–199 mg/dL during an oral glucose tolerance test (OGTT) — a range that falls squarely in the prediabetes zone by both Japanese and American standards. Participants were randomly assigned to receive low (730 mg/day), medium (970 mg/day), or high (1,460 mg/day) daily doses of myristic acid in soft capsules, or a placebo, for 12 weeks. The trial was double-blinded, randomized, and placebo-controlled — the gold standard for clinical research.

What They Found

The results were notable. Participants taking the medium dose (970 mg/day) saw their post-meal blood sugar response — measured as the incremental area under the curve (iAUC) — drop by approximately 20% compared to the placebo group (78.8 vs. 101.4 mg/dL·h). At the 60-minute mark after glucose loading, blood sugar was 23 mg/dL lower than placebo — a clinically meaningful difference.

The high dose (1,460 mg/day) group showed similar benefits: a ~20% reduction in overall post-meal glucose response and a peak blood sugar (Cmax) that was 11.4 mg/dL lower than placebo. The low dose showed no significant effect, suggesting there is a minimum effective threshold.

Importantly, fasting insulin levels were slightly higher in the medium- and high-dose groups, hinting that myristic acid may support insulin secretion — though researchers noted this needs further study. No adverse events were reported.

Why This Matters for US Patients

According to the CDC, more than 98 million Americans — roughly 1 in 3 adults — have prediabetes, and most don't know it. The American Diabetes Association (ADA) defines prediabetes as a post-meal glucose of 140–199 mg/dL during an OGTT, which is exactly the population studied here. Current US prevention strategies focus heavily on lifestyle changes: weight loss, exercise, and dietary modifications. This Japanese research introduces a novel nutritional angle — that a specific saturated fatty acid, taken in small, targeted amounts, might become a complementary tool in that prevention toolkit.

It's worth noting that US dietary guidelines generally caution against high saturated fat intake due to cardiovascular risk. However, the doses used in this study (730–1,460 mg/day) are far below what most Americans consume in a typical diet, and no safety concerns were observed. This distinction is important: the goal isn't to add butter to everything, but to explore whether a precise, low-dose supplement form could offer benefit.

The international perspective here is valuable because Japan's approach to functional food research — rigorously testing specific food components in clinical trials — often precedes mainstream adoption in the US. American researchers and clinicians can look to studies like this as an early signal worth watching.

The Bottom Line

Myristic acid is not a replacement for medication or lifestyle change, and the researchers themselves call for longer-term studies. But for US patients in the prediabetes range looking for every evidence-based edge, this Japanese trial offers a genuinely promising lead. Talk to your healthcare provider before adding any new supplement to your routine.

Original study: Sato, Nishimura, Aoki. "Suppressive effect of myristic acid on postprandial blood glucose elevation in healthy adults with high blood glucose levels." Clinical Nutrition ESPEN, 2026. PMID: 41314609. DOI: 10.1016/j.clnesp.2025.11.148